BR0012325A - Methods and compositions for preventing the formation of abnormal RNA during the transcription of a plasmid sequence - Google Patents

Methods and compositions for preventing the formation of abnormal RNA during the transcription of a plasmid sequence

Info

Publication number
BR0012325A
BR0012325A BR0012325-0A BR0012325A BR0012325A BR 0012325 A BR0012325 A BR 0012325A BR 0012325 A BR0012325 A BR 0012325A BR 0012325 A BR0012325 A BR 0012325A
Authority
BR
Brazil
Prior art keywords
methods
compositions
preventing
molecules
transcription
Prior art date
Application number
BR0012325-0A
Other languages
Portuguese (pt)
Inventor
C Satishchandran
Catherine J Pachuk
Original Assignee
American Home Prod
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by American Home Prod filed Critical American Home Prod
Publication of BR0012325A publication Critical patent/BR0012325A/en

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N15/00—Mutation or genetic engineering; DNA or RNA concerning genetic engineering, vectors, e.g. plasmids, or their isolation, preparation or purification; Use of hosts therefor
    • C12N15/09—Recombinant DNA-technology
    • C12N15/11—DNA or RNA fragments; Modified forms thereof; Non-coding nucleic acids having a biological activity
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N15/00—Mutation or genetic engineering; DNA or RNA concerning genetic engineering, vectors, e.g. plasmids, or their isolation, preparation or purification; Use of hosts therefor
    • C12N15/09—Recombinant DNA-technology
    • C12N15/63—Introduction of foreign genetic material using vectors; Vectors; Use of hosts therefor; Regulation of expression
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/12—Antivirals
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • C07K14/52—Cytokines; Lymphokines; Interferons
    • C07K14/54—Interleukins [IL]
    • C07K14/5434—IL-12
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N15/00—Mutation or genetic engineering; DNA or RNA concerning genetic engineering, vectors, e.g. plasmids, or their isolation, preparation or purification; Use of hosts therefor
    • C12N15/09—Recombinant DNA-technology
    • C12N15/63—Introduction of foreign genetic material using vectors; Vectors; Use of hosts therefor; Regulation of expression
    • C12N15/67—General methods for enhancing the expression

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Genetics & Genomics (AREA)
  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Engineering & Computer Science (AREA)
  • Zoology (AREA)
  • Biomedical Technology (AREA)
  • Wood Science & Technology (AREA)
  • General Health & Medical Sciences (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • General Engineering & Computer Science (AREA)
  • Biotechnology (AREA)
  • Molecular Biology (AREA)
  • Biophysics (AREA)
  • Biochemistry (AREA)
  • Medicinal Chemistry (AREA)
  • Microbiology (AREA)
  • Plant Pathology (AREA)
  • Physics & Mathematics (AREA)
  • General Chemical & Material Sciences (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • Animal Behavior & Ethology (AREA)
  • Communicable Diseases (AREA)
  • Virology (AREA)
  • Oncology (AREA)
  • Toxicology (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Micro-Organisms Or Cultivation Processes Thereof (AREA)
  • Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)

Abstract

"MéTODOS E COMPOSIçõES PARA PREVENçãO DA FORMAçãO DE RNA ANORMAL DURANTE A TRANSCRIçãO DE UMA SEQuêNCIA DE PLASMìDEO". Moléculas de polinucleotídeo, as quais incluem DNA ou RNA de filamento simples, DNA de filamento parcialmente duplo, e moléculas de DNA de filamento duplo, contêm seq³ências de terminador e/ou outras modificações que suprimem a produção de espécies de polinucleotídeo indesejadas a partir dessas moléculas quando transfectadas em uma célula hospedeira. Essas moléculas são úteis em métodos para aumento da eficiência de transcrição de uma sequência de polinucleotídeo selecionada em uma célula hospedeira transfectada, e redução do potencial para os produtos de transcritos indesejados. Ainda, os métodos da invenção são úteis ao evitar a extinção ou regulagem inferior da expressão de certos polinucleotídeos presentes em uma célula hospedeira ou hospedeiro. Essas composições e métodos são úteis nos campos terapêutico, de vacina, de diagnóstico e de pesquisa."METHODS AND COMPOSITIONS FOR PREVENTING THE FORMATION OF ABNORMAL RNA DURING THE TRANSCRIPTION OF A PLASMID SEQUENCE". Polynucleotide molecules, which include single-stranded DNA or RNA, partially double-stranded DNA, and double-stranded DNA molecules, contain terminator sequences and / or other modifications that suppress the production of unwanted polynucleotide species from these molecules when transfected into a host cell. These molecules are useful in methods for increasing the transcription efficiency of a selected polynucleotide sequence in a transfected host cell, and reducing the potential for unwanted transcript products. In addition, the methods of the invention are useful in preventing extinction or under-regulation of the expression of certain polynucleotides present in a host cell or host. These compositions and methods are useful in the therapeutic, vaccine, diagnostic and research fields.

BR0012325-0A 1999-07-09 2000-06-27 Methods and compositions for preventing the formation of abnormal RNA during the transcription of a plasmid sequence BR0012325A (en)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US14305999P 1999-07-09 1999-07-09
PCT/US2000/017670 WO2001004313A1 (en) 1999-07-09 2000-06-27 Methods and compositions for preventing the formation of aberrant rna during transcription of a plasmid sequence

Publications (1)

Publication Number Publication Date
BR0012325A true BR0012325A (en) 2002-05-21

Family

ID=22502421

Family Applications (1)

Application Number Title Priority Date Filing Date
BR0012325-0A BR0012325A (en) 1999-07-09 2000-06-27 Methods and compositions for preventing the formation of abnormal RNA during the transcription of a plasmid sequence

Country Status (10)

Country Link
EP (1) EP1194556A1 (en)
JP (1) JP2003504061A (en)
KR (1) KR20020030780A (en)
CN (1) CN1360631A (en)
AU (1) AU783681B2 (en)
BR (1) BR0012325A (en)
CA (1) CA2378653A1 (en)
IL (1) IL147026A0 (en)
MX (1) MXPA01013462A (en)
WO (1) WO2001004313A1 (en)

Families Citing this family (53)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
NZ506648A (en) 1998-03-20 2003-08-29 Benitec Australia Ltd Control of gene expression through introduction of synthetic tandem repeats to reduce translation of mRNA
AUPP249298A0 (en) 1998-03-20 1998-04-23 Ag-Gene Australia Limited Synthetic genes and genetic constructs comprising same I
CA2361201A1 (en) 1999-01-28 2000-08-03 Medical College Of Georgia Research Institute, Inc. Composition and method for in vivo and in vitro attenuation of gene expression using double stranded rna
US7601494B2 (en) 1999-03-17 2009-10-13 The University Of North Carolina At Chapel Hill Method of screening candidate compounds for susceptibility to biliary excretion
US6423885B1 (en) 1999-08-13 2002-07-23 Commonwealth Scientific And Industrial Research Organization (Csiro) Methods for obtaining modified phenotypes in plant cells
US8202979B2 (en) 2002-02-20 2012-06-19 Sirna Therapeutics, Inc. RNA interference mediated inhibition of gene expression using chemically modified short interfering nucleic acid
AU2001249170A1 (en) * 2000-03-13 2001-09-24 Aptagen Method for modifying a nucleic acid
US20020132257A1 (en) 2001-01-31 2002-09-19 Tony Giordano Use of post-transcriptional gene silencing for identifying nucleic acid sequences that modulate the function of a cell
US6630589B1 (en) 2001-03-26 2003-10-07 Message Pharmaceuticals Identification of compounds for the treatment or prevention of proliferative diseases
US20050148530A1 (en) 2002-02-20 2005-07-07 Sirna Therapeutics, Inc. RNA interference mediated inhibition of vascular endothelial growth factor and vascular endothelial growth factor receptor gene expression using short interfering nucleic acid (siNA)
US9994853B2 (en) 2001-05-18 2018-06-12 Sirna Therapeutics, Inc. Chemically modified multifunctional short interfering nucleic acid molecules that mediate RNA interference
US7109165B2 (en) 2001-05-18 2006-09-19 Sirna Therapeutics, Inc. Conjugates and compositions for cellular delivery
DE50214801D1 (en) 2001-06-05 2011-01-13 Curevac Gmbh Stabilized mRNA with increased G / C content, coding for a viral antigen
US7897382B2 (en) 2001-10-22 2011-03-01 Alnylam Pharmaceuticals, Inc. Transfection kinetics and structural promoters
DE10162480A1 (en) 2001-12-19 2003-08-07 Ingmar Hoerr The application of mRNA for use as a therapeutic agent against tumor diseases
US9181551B2 (en) 2002-02-20 2015-11-10 Sirna Therapeutics, Inc. RNA interference mediated inhibition of gene expression using chemically modified short interfering nucleic acid (siNA)
US9657294B2 (en) 2002-02-20 2017-05-23 Sirna Therapeutics, Inc. RNA interference mediated inhibition of gene expression using chemically modified short interfering nucleic acid (siNA)
AU2003207708A1 (en) 2002-02-20 2003-09-09 Sirna Therapeutics, Inc. Rna interference mediated inhibition of map kinase genes
US20040180438A1 (en) 2002-04-26 2004-09-16 Pachuk Catherine J. Methods and compositions for silencing genes without inducing toxicity
DE10229872A1 (en) 2002-07-03 2004-01-29 Curevac Gmbh Immune stimulation through chemically modified RNA
EP1623009A4 (en) * 2003-04-22 2008-02-13 Nucleonics Inc Transfection kinetics and structural promoters
ATE452188T1 (en) 2004-02-10 2010-01-15 Sirna Therapeutics Inc RNA INTERFERENCE-MEDIATED INHIBITION OF GENE EXPRESSION USING MULTIFUNCTIONAL SINA (SHORT INTERFERING NUCLEIC ACID)
WO2005078848A2 (en) 2004-02-11 2005-08-25 University Of Tennessee Research Foundation Inhibition of tumor growth and invasion by anti-matrix metalloproteinase dnazymes
AU2005222965B8 (en) 2004-03-15 2010-07-01 City Of Hope Methods and compositions for the specific inhibition of gene expression by double-stranded RNA
US20070265220A1 (en) 2004-03-15 2007-11-15 City Of Hope Methods and compositions for the specific inhibition of gene expression by double-stranded RNA
WO2005105157A2 (en) 2004-04-23 2005-11-10 The Trustees Of Columbia University In The City Ofnew York INHIBITION OF HAIRLESS PROTEIN mRNA
US10508277B2 (en) 2004-05-24 2019-12-17 Sirna Therapeutics, Inc. Chemically modified multifunctional short interfering nucleic acid molecules that mediate RNA interference
CA2579574A1 (en) 2004-07-23 2007-01-04 The University Of North Carolina At Chapel Hill Methods and materials for determining pain sensitivity and predicting and treating related disorders
WO2007011702A2 (en) 2005-07-15 2007-01-25 The University Of North Carolina At Chapel Hill Use of egfr inhibitors to prevent or treat obesity
US9708619B2 (en) 2005-09-20 2017-07-18 Basf Plant Science Gmbh Methods for controlling gene expression using ta-siRNA
JP2010516786A (en) 2007-01-26 2010-05-20 ユニバーシティー オブ ルイヴィル リサーチ ファウンデーション，インコーポレーテッド Modification of exosome components for use as a vaccine
ES2538217T3 (en) 2007-03-21 2015-06-18 Brookhaven Science Associates, Llc Combined fork antisense compositions and methods to modulate expression
AR079494A1 (en) 2009-12-18 2012-02-01 Novartis Ag ORGANIC COMPOSITIONS TO TREAT DISEASES RELATED TO THE HEAT SHOCK FACTOR 1 HSF1
IN2012DN06588A (en) 2010-02-10 2015-10-23 Novartis Ag
CA2807552A1 (en) 2010-08-06 2012-02-09 Moderna Therapeutics, Inc. Engineered nucleic acids and methods of use thereof
BR112013007862A2 (en) 2010-10-01 2019-09-24 Moderna Therapeutics Inc manipulated nucleic acids and methods of use thereof.
EP3766975A1 (en) 2010-10-29 2021-01-20 Sirna Therapeutics, Inc. Rna interference mediated inhibition of gene expression using short interfering nucleic acid (sina)
AU2012236099A1 (en) 2011-03-31 2013-10-03 Moderna Therapeutics, Inc. Delivery and formulation of engineered nucleic acids
US9464124B2 (en) 2011-09-12 2016-10-11 Moderna Therapeutics, Inc. Engineered nucleic acids and methods of use thereof
HUE057725T2 (en) 2011-10-03 2022-06-28 Modernatx Inc Modified nucleosides, nucleotides, and nucleic acids, and uses thereof
PT2791160T (en) 2011-12-16 2022-07-04 Modernatx Inc Modified nucleoside, nucleotide, and nucleic acid compositions
WO2013105022A2 (en) 2012-01-09 2013-07-18 Novartis Ag Organic compositions to treat beta-catenin-related diseases
US9572897B2 (en) 2012-04-02 2017-02-21 Modernatx, Inc. Modified polynucleotides for the production of cytoplasmic and cytoskeletal proteins
US9254311B2 (en) 2012-04-02 2016-02-09 Moderna Therapeutics, Inc. Modified polynucleotides for the production of proteins
US9283287B2 (en) 2012-04-02 2016-03-15 Moderna Therapeutics, Inc. Modified polynucleotides for the production of nuclear proteins
JP6189415B2 (en) 2012-04-02 2017-08-30 モデルナティエックス インコーポレイテッドＭｏｄｅｒｎａＴＸ，Ｉｎｃ． Modified polynucleotides for the production of cytoplasmic and cytoskeletal proteins
LT2922554T (en) 2012-11-26 2022-06-27 Modernatx, Inc. Terminally modified rna
US8980864B2 (en) 2013-03-15 2015-03-17 Moderna Therapeutics, Inc. Compositions and methods of altering cholesterol levels
WO2015048744A2 (en) 2013-09-30 2015-04-02 Moderna Therapeutics, Inc. Polynucleotides encoding immune modulating polypeptides
MX2016004249A (en) 2013-10-03 2016-11-08 Moderna Therapeutics Inc Polynucleotides encoding low density lipoprotein receptor.
WO2015062738A1 (en) 2013-11-01 2015-05-07 Curevac Gmbh Modified rna with decreased immunostimulatory properties
US11072777B2 (en) 2016-03-04 2021-07-27 University Of Louisville Research Foundation, Inc. Methods and compositions for ex vivo expansion of very small embryonic-like stem cells (VSELs)
US20200362345A1 (en) * 2019-05-17 2020-11-19 Massachusetts Institute Of Technology Engineered post-poly a signal rna and uses thereof

Family Cites Families (5)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US5587300A (en) * 1994-04-26 1996-12-24 Wisconsin Ulumni Research Foundation Method to increase regulatory molecule production
US5888774A (en) * 1994-12-19 1999-03-30 Cangene Corporation Recombinant DNA molecules and expression vectors for erythropoietin
US6022863A (en) * 1996-05-21 2000-02-08 Yale University Regulation of gene expression
WO1999010509A1 (en) * 1997-08-22 1999-03-04 The Government Of The United States Of America, Represented By The Secretary Of Health And Human Services, National Institutes Of Health Polynucleotide inhibition of rna destabilization and sequestration
CA2304982A1 (en) * 1997-09-19 1999-03-25 Sequitur, Inc. Sense mrna therapy

Also Published As

Publication number Publication date
MXPA01013462A (en) 2002-07-02
AU783681B2 (en) 2005-11-24
EP1194556A1 (en) 2002-04-10
AU5893700A (en) 2001-01-30
IL147026A0 (en) 2002-08-14
JP2003504061A (en) 2003-02-04
WO2001004313A1 (en) 2001-01-18
CA2378653A1 (en) 2001-01-18
CN1360631A (en) 2002-07-24
KR20020030780A (en) 2002-04-25

Similar Documents

Publication Publication Date Title
BR0012325A (en) Methods and compositions for preventing the formation of abnormal RNA during the transcription of a plasmid sequence
EP3359677B1 (en) Compositions and methods for treating fragile x syndrome and related syndromes
WO2018179578A1 (en) Method for inducing exon skipping by genome editing
HK1244504A1 (en) Antisense design
CN107532162A (en) For the composition and method using oligonucleotides editor's cell amplifying nucleic acid
GB2397062A (en) RNA interference mediated inhibition of hepatitis c virus (HCV) gene expression using short interfering nucleic acid (siNA)
DK1929012T3 (en) Method of in vitro recombination
GB2397818A (en) Rna interference mediated inhibition of gene expression using chemically modified short interfering nucleic acid
EP2014776A3 (en) Diagnosis of diseases associated with DNA transcription
EP2631294A3 (en) Human microRNAs and methods for inhibiting same
DE69936104D1 (en) NUCLEIC ACID SEQUENCES OF ADENO-ASSOCIATED VIRUS OF SEROTYPE I, AND VECTORS AND HOST CELLS THEREOF CONTAINING THEM
IL166546A (en) Double stranded ribonucleic acid, composition containing same, use thereof in the preparation of medicaments and an in vitro method for inhibiting the expression of a target gene
ATE239090T1 (en) METHOD FOR GENERATING SINGLE STRANDED DNA MOLECULES
MXPA03002413A (en) B7-like molecules and uses thereof.
EP3040423A3 (en) Microrna and uses thereof
DE69934227D1 (en) ON BETA ARABINOSIS, AND ITS ANALOGS, BASED ANTISENSE OLIGONUCLEOTIDES
WO1998026093A3 (en) Fluorescent nucleotide analog hairpin formation for detection of nucleic acid hybridization
WO2000078968A3 (en) Nucleotide sequences of moraxella catarrhalis genome
WO2004001013A3 (en) Inhibition of gene expression in vertebrates using double-stranded rna (rnai)
EP1268507A4 (en) Antisense modulation of e2f transcription factor 1 expression
WO2000015209A3 (en) REGULATION OF HER2/neu ONCONGENE EXPRESSION BY SYNTHETIC POLYAMIDES
HUP0101355A2 (en) Genomic sequences upstream of the coding region of the g-csf gene for protein production and delivery
WO2001071036A3 (en) Methods of preparing amplified nucleic acid molecules
CN114981445A (en) Modified double stranded donor templates
HK1090663A1 (en) Chicken rna polymerase i promoter and the use thereof

Legal Events

Date Code Title Description
B25D Requested change of name of applicant approved
B08F Application dismissed because of non-payment of annual fees [chapter 8.6 patent gazette]

Free format text: REFERENTE A 7A, 8A E 9A ANUIDADES

B08K Patent lapsed as no evidence of payment of the annual fee has been furnished to inpi [chapter 8.11 patent gazette]

Free format text: REFERENTE AO DESPACHO 8.6 DA RPI 2008 DE 30/06/2009.